Fulcrum Therapeutics (NASDAQ:FULC) Releases Earnings Results, Hits Expectations

Fulcrum Therapeutics (NASDAQ:FULC) posted its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.31), Zacks reports.

Here are the key takeaways from Fulcrum Therapeutics’ conference call:

• Robust 12-week biological response — the 20 mg cohort showed a mean absolute HbF rise from baseline 7.1% to 19.3% (+12.2%), >50% of patients reached ≥20% HbF, F‑cells roughly doubled to ~63%, LDH and indirect bilirubin fell (~34% and ~40%), and mean total hemoglobin increased by ~1.1 g/dL.
• Encouraging but exploratory VOC signal — 7 of 12 evaluable patients had no VOCs during treatment and the cohort observed 6 VOCs versus an expected 16 based on baseline, yet the study is small (12 PD-evaluable patients), 12 weeks is short, and VOCs were not a powered or adjudicated endpoint, so clinical impact on VOCs remains unproven.
• Safety and dose selection support advancing the program — pociredir at 20 mg was generally well tolerated with no treatment-related serious adverse events and no treatment-related discontinuations, and the company reports no additional HBG mRNA induction at 30 mg, so 20 mg is the dose being taken forward.
• Clear development path and external endorsement — Fulcrum plans an FDA meeting (Q2 2026), aims to start a potential registration‑enabling trial in H2 2026, will seek EMA protocol assistance, is activating an open‑label extension, and independent expert Dr. Martin Steinberg characterized the data as potentially supporting a first‑line or combination oral HbF inducer; the company cites a ~2‑year lead over next competitors.

Fulcrum Therapeutics Trading Up 4.7%

FULC opened at $8.98 on Thursday. The company has a market cap of $486.00 million, a price-to-earnings ratio of -7.61 and a beta of 3.19. The company’s 50 day moving average is $10.73 and its 200 day moving average is $9.48. Fulcrum Therapeutics has a 12-month low of $2.32 and a 12-month high of $15.74.

Wall Street Analyst Weigh In

A number of research firms have recently commented on FULC. Cantor Fitzgerald increased their price target on shares of Fulcrum Therapeutics from $15.00 to $24.00 and gave the company an “overweight” rating in a report on Monday, December 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Thursday, January 22nd. Piper Sandler restated an “overweight” rating and issued a $23.00 price target (up from $16.00) on shares of Fulcrum Therapeutics in a research note on Monday, December 8th. Wall Street Zen cut Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 17th. Finally, JPMorgan Chase & Co. began coverage on Fulcrum Therapeutics in a report on Monday, January 12th. They issued an “overweight” rating and a $20.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Fulcrum Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

More Fulcrum Therapeutics News

Here are the key news stories impacting Fulcrum Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near‑term losses and raised FY2026/FY2027 forecasts while keeping a “Buy” rating and a $25 target — the firm moved Q1–Q4 2026 quarterly EPS views to ($0.28) (from $0.29) and lifted FY2026 to ($1.12) from ($1.16), signaling slightly improved near‑term fundamentals and reaffirming a high upside target. MarketBeat FULC Coverage
• Positive Sentiment: Press coverage highlights “promising clinical trial data” and a strong cash runway that supported a buying push — positive trial readouts and a runway narrative can justify re‑rating for a biotech with a path to commercialization. Shares Surge on Promising Clinical Trial Data
• Positive Sentiment: Stifel called the prior sell‑off “overdone,” offering a supportive contrarian take that can attract value/relative‑value buyers and help stabilize the stock. Stifel Says Move Lower ‘Overdone’
• Neutral Sentiment: Q4 2025 earnings materials/transcript show Fulcrum reported EPS roughly in line with expectations and discussed development progress — provides context but contained no surprise guidance to materially change near‑term valuation. Q4 2025 Earnings Call Transcript Earnings Call Summary
• Negative Sentiment: Some outlets reported that the stock previously “tumbled despite trial results,” indicating profit‑taking, valuation concerns, or investor desire for longer follow‑up data — that recent volatility explains why investor sentiment remains mixed even after positive analyst moves. Stock Tumbles Despite Trial Results

Insider Buying and Selling

In other Fulcrum Therapeutics news, Director Robert J. Gould sold 15,000 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $11.87, for a total value of $178,050.00. Following the transaction, the director directly owned 469,864 shares in the company, valued at approximately $5,577,285.68. This trade represents a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of Fulcrum Therapeutics stock in a transaction on Monday, December 8th. The stock was sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the transaction, the insider owned 6,053,960 shares in the company, valued at $84,634,360.80. This represents a 40.82% decrease in their position. The SEC filing for this sale provides additional information. 7.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Fulcrum Therapeutics

Hedge funds have recently bought and sold shares of the stock. Invesco Ltd. raised its stake in shares of Fulcrum Therapeutics by 236.8% in the fourth quarter. Invesco Ltd. now owns 417,189 shares of the company’s stock worth $4,718,000 after buying an additional 293,317 shares during the period. XTX Topco Ltd bought a new position in shares of Fulcrum Therapeutics during the 4th quarter valued at approximately $586,000. Ikarian Capital LLC increased its holdings in Fulcrum Therapeutics by 6.7% in the 4th quarter. Ikarian Capital LLC now owns 1,375,472 shares of the company’s stock worth $15,557,000 after acquiring an additional 86,247 shares in the last quarter. Vestal Point Capital LP bought a new stake in Fulcrum Therapeutics during the 4th quarter worth approximately $10,744,000. Finally, Virtus Investment Advisers LLC purchased a new position in Fulcrum Therapeutics during the fourth quarter valued at approximately $231,000. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.